Skip to content
2000
Volume 10, Issue 1
  • ISSN: 2667-3371
  • E-ISSN: 2667-338X

Abstract

Many non-biological drugs, different in terms of their structure and mode of action, pharmacological classification, and therapeutic indication, have a common factor of structural complexity and are grouped as non-biological complex drugs (NBCDs). When an innovator drug nears the time of off-patent, different manufacturers attempt to produce its subsequent version, so the patients will have a cost-effective therapeutic equivalent. Since the innovator molecule is complex, its follow-on drug can be called its true generic version, if its bioavailability, bioequivalence and therapeutic equivalence to the innovator drug are demonstrated. However, it is observed that a case-to-case basis approach is implemented by European Medicines Agency (EMA) and Food and Drug Administration, US (USFDA) in the approval of such drugs and there is no uniformity observed between the two.

In this study, an attempt is made to study the complexity of molecules compare and understand the data requirements, and procedures adopted for the review and approval of such complex products. Therefore, drug sevelamer carbonate and glatiramer acetate are selected for the study. A methodical approach was followed. European assessment reports and drug approvals available in the orange book database of the former two regulatory agencies were studied. It is observed that the generic version of glatiramer acetate is approved as an abbreviated new drug application (ANDA) by Food and Drug Administration whereas the same was approved as the hybrid application by European Medicines Agency requiring the applicant to generate and submit more data. Thus, harmonization of the regulatory requirements for the approval of follow-on versions of such complex drugs is essential for better understanding, predictability of the regulatory process, and acceleration of the drug approval process, in the interest of patients. This will help the faster access of the drugs to the patients and allow interchangeability of the innovator drugs with its cost-effective generic version.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/adctra/10.2174/2667337109666230428094012
2023-05-08
2026-02-27

  • From This Site

    /content/journals/adctra/10.2174/2667337109666230428094012
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. JonesH.W. ParkI.J. RockJ.A. Technique of surgical sex reassignment for micropenis and allied conditions.Am. J. Obstet. Gynecol.1978132887087710.1016/0002‑9378(78)90714‑7 367161
     [Google Scholar]
  2. KoblishM. CarrR.III SiudaE.R. TRV0109101, a G Protein-Biased agonist of the m-opioid receptor, does not promote opioid-induced mechanical allodynia following chronic administration.J. Pharmacol. Exp. Ther.2017362225426210.1124/jpet.117.241117 28533287
     [Google Scholar]
  3. SwansonB.N. Delivery of high-quality biomarker assays.Dis. Markers2002182475610.1155/2002/212987 12364810
     [Google Scholar]
  4. SviestinaI. MozgisD. A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia.Eur. J. Hosp. Pharm. Sci. Pract.201825417618210.1136/ejhpharm‑2016‑001107 31157015
     [Google Scholar]
  5. OkaY. MiyazakiM. TakatsuS. A review article: Sevelamer hydrochloride and metabolic acidosis in dialysis patients.Cardiovasc. Hematol. Disord. Drug Targets20088428328610.2174/187152908786786197 19075639
     [Google Scholar]
  6. DaiZ. DengJ. AnsaloniL. JanakiramS. DengL. Thin-film-composite hollow fiber membranes containing amino acid salts as mobile carriers for CO2 separation.J. Membr. Sci.2019578616810.1016/j.memsci.2019.02.023
     [Google Scholar]
  7. McElhattonA. José do Amaral SobralP. Novel technologies in food science.1st edNew YorkSpringer2012
     [Google Scholar]
  8. DohertyE. A comparison of the physiology of free and immobilised cells.J. Chem. Technol. Biotechnol.199151227727810.1002/jctb.280510217
     [Google Scholar]
  9. YanQ.Z. YangY.H. HuangY.L. Cost-effective bypass design of highly controllable heat-exchanger networks.AIChE J.200147102253227610.1002/aic.690471012
     [Google Scholar]
  10. In vitro analysis of follow-on versions of sevelamer.2022
     [Google Scholar]
  11. SinghS.S. SachanS. PandeyV. Farmers participatory intervention for management of shoot gall psylla, Apsylla cistellata Buckton in mango.J. Entomol. Res.201741443744210.5958/0974‑4576.2017.00072.X
     [Google Scholar]
  12. Di BattistaT. FortunaF. MaturoF. Environmental monitoring through functional biodiversity tools.Ecol. Indic.20166023724710.1016/j.ecolind.2015.05.056
     [Google Scholar]
  13. DeMottJ.M.Jr JahngenE.G.E. Determination of amino acids at a silver oxide/silver phosphate electrode and the analysis of structure-response relationships.Electroanalysis200517759960610.1002/elan.200303128
     [Google Scholar]
  14. XiongX. FengY. Process quality indices: New metrics for process quality capability with zero-loss baseline.Total Qual. Manage. Bus. Excell.2022339-1097599310.1080/14783363.2021.1911634
     [Google Scholar]
  15. JainS. KhireV.H. KandasubramanianB. Barium titanate: A novel perovskite oxide burning rate modifier for HTPB/AP/Al based composite propellant formulations.Propellants Explos. Pyrotech.201944450551210.1002/prep.201800167
     [Google Scholar]
  16. LeeD.H. ZoY.G. KimS.J. Nonradioactive method to study genetic profiles of natural bacterial communities by PCR-single-strand-conformation polymorphism.Appl. Environ. Microbiol.19966293112312010.1128/aem.62.9.3112‑3120.1996 8795197
     [Google Scholar]
  17. DalgleishA. CopierJ. New multitargeted treatments with antiangiogenic and antitumor activity: Focus on sunitinib.Target. Oncol.200721172910.1007/s11523‑006‑0040‑3
     [Google Scholar]
  18. CookD. BrownD. AlexanderR. Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework.Nat. Rev. Drug Discov.201413641943110.1038/nrd4309 24833294
     [Google Scholar]
  19. FDA Should Make Public Its Plans to Issue and Revise Guidance on Nonbiological Complex Drugs.2022Available from: https://www.gao.gov/products/gao-18-80
  20. IshikawaY. NiwanoT. HiranoS. NumanoK. TakasimaK. ImokawaG. Whitening effect of l-ascorbate-2-phosphate trisodium salt on solar lentigos.Arch. Dermatol. Res.2019311318319110.1007/s00403‑019‑01892‑2 30778667
     [Google Scholar]
  21. BaronJ. SpulberD.F. Technology standards and standard setting organizations: Introduction to the searle center database.J. Econ. Manag. Strategy2018273462503https://ssrn.com/abstract=307316510.2139/ssrn.3073165
     [Google Scholar]
  22. The FDA's drug review process: Ensuring drugs are safe and effective. US Food and Drug Administration (FDA). 2023Available from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-
/content/journals/adctra/10.2174/2667337109666230428094012
Loading
A Comparative Study on Approval of Follow-on Version of Sevelamer Carbonate and Glatiramer Acetate (GA) in US, EU
Appl. Drug Resea., Clin. Trials and Regu. Affa. 10, E280423216310 (2024); https://doi.org/10.2174/2667337109666230428094012
/content/journals/adctra/10.2174/2667337109666230428094012
/content/journals/adctra/10.2174/2667337109666230428094012
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): follow-on version; glatiramer acetate; innovator; non-biological complex drugs; patients; Sevelamer carbonate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test